NanoViricides Expects NV-387 Ebola Trial to Advance to Phase IIB After Phase IIA Completion

PUBT · 6d ago
NanoViricides Expects NV-387 Ebola Trial to Advance to Phase IIB After Phase IIA Completion
  • NanoViricides reported its Phase IIA trial of NV-387 Oral Gummies for Ebola is progressing well, with advancement to Phase IIB expected upon completion.
  • Enrollment began Sept. 23, 2026, in the Democratic Republic of Congo; the ongoing study evaluates dosing based on disease severity.
  • The treatment targets Ebola Bundibugyo, for which no treatment or vaccine is currently approved.
  • NV-387 Oral Gummies is also undergoing a Phase II trial for mpox in the Democratic Republic of Congo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610270915ACCESSWRNAPR_____1242462) on October 27, 2026, and is solely responsible for the information contained therein.